Liangxing Zou, PhD

Cogent Biosciences
Waltham, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Paper 62 - PEAK STUDY: A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB COMBINATION VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)

  Saturday, November 4, 2023
  9:00 AM – 10:00 AM